|
1
|
Garcia-Manero G: Myelodysplastic
syndromes: 2015 Update on diagnosis, risk-stratification and
management. Am J Hematol. 90:831–841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nimer SD: Myelodysplastic syndromes.
Blood. 111:4841–4851. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brunning RD, Orazi A, Germing U, Le Beau
Porwit, Baumann I, Vardiman JW and Hellstrom-Lindberg E:
Myelodysplastic syndromes/neoplasms, overview. WHO Classification
of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH,
Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and
Vardiman JW: (4th). IARC Press. (Lyon). 87–93. 2008.
|
|
4
|
Foucar K:
Myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol.
132:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sekeres MA: The epidemiology of
myelodysplastic syndromes. Hematol Oncol Clin North Am. 24:287–294.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cabello AI, Collado R, Ruiz MA, Martínez
J, Navarro I, Ferrer R, Sosa AM and Carbonell F: A retrospective
analysis of myelodysplastic syndromes with thrombocytosis:
Reclassification of the cases by WHO proposals. Leuk Res.
29:365–370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al:
International prognostic scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
|
|
8
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognosis scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haase D, Germing U, Schanz J, Pfeilstöcker
M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R,
Giagounidis AA, et al: New insights into the prognostic impact of
the karyotype in MDS and correlation with subtypes: Evidence from a
core dataset of 2124 patients. Blood. 110:4385–4395. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moyo V, Lefebvre P, Duh MS, Yektashenas B
and Mundle S: Erythropoiesis-stimulating agents in the treatment of
anemia in myelodysplastic syndromes: A meta-analysis. Ann Hematol.
87:527–536. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
List A, Dewald G, Bennett J, Giagounidis
A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, et
al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q
deletion. N Engl J Med. 355:1456–1465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fenaux P, Giagounidis A, Selleslag D,
Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz
G, Del Cañizo C, et al: A randomized phase 3 study of lenalidomide
versus placebo in RBC transfusion-dependent patients with
low-/intermediate-1 risk myelodysplastic syndromes with del5q.
Blood. 118:3765–3776. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fenaux P and Adès L: How we treat
lower-risk myelodysplastc syndromes. Blood. 121:4280–4286. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fenaux P, Haase D, Sanz GF, Santini V and
Buske ESMO: Guidelines Working Group: Myelodysplastic syndromes:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 25(Suppl 3): iii57–iii69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garcia-Manero G: Myelodysplastic
syndromes: 2014 update on diagnosis, risk-stratification, and
management. Am J Hematol. 89:97–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeromin S, Haferlach T, Weissmann S,
Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern
W, Haferlach C and Schnittger S: Refractory anemia with ring
sideroblasts and marked thrombocytosis cases harbor mutations in
SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1
mutations. Haematologica. 100:e125–e127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Murphy S, Peterson P, Iland H and Laszlo
J: Experience of the Polycythemia Vera study group with essential
thrombocythemia: A final report on diagnostic criteria, survival,
and leukemic transition by treatment. Semin Hematol. 34:29–39.
1997.PubMed/NCBI
|
|
18
|
Steensma DP: JAK2 V617F in myeloid
disorders: Molecular diagnostic techniques and their clinical
utility: A paper from the 2005 William Beaumont Hospital Symposium
on Molecular Pathology. J Mol Diagn. 8:397–411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vardiman JBR, Bennett JM, Bain BJ, Baumann
I, Thiele J and Orazi A: Myelodysplastic/myeloproliferative
neoplasm, unclassifiable. WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris
NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW: IARC
Press. (Lyon). 85–86. 2008.
|
|
20
|
Orazi A and Germing U: The
myelodysplastic/myeloproliferative neoplasms: Myeloproliferative
diseases with dysplastic features. Leukemia. 22:1308–1319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szpurka H, Tiu R, Murugesan G, Aboudola S,
Hsi ED, Theil KS, Sekeres MA and Maciejewski JP: Refractory anemia
with ringed sideroblasts associated with marked thrombocytosis
(RARS-T), another myeloproliferative condition characterized by
JAK2 V617F mutation. Blood. 108:2173–2181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Malcovati L and Cazzola M: Refractory
anemia with ring sideroblasts. Best Pract Res Clin Haematol.
26:377–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patnaik MM and Tefferi A: Refractory
anemia with ring sideroblasts and RARS with thrombocytosis. Am J
Hematol. 90:549–559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mikoczy Z, Schütz A and Hagmar L: Cancer
incidence and mortality among Swedish leather tanners. Occup
Environ Med. 51:530–535. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mikoczy Z, Schütz A, Strömberg U and
Hagmar L: Cancer incidence and specific occupational exposures in
the Swedish leather tanning industry: A cohort based case-control
study. Occup Environ Med. 53:463–467. 1996. View Article : Google Scholar : PubMed/NCBI
|
